Association of genetic variants in and promoter hypermethylation of CDH1 with gastric cancer: A meta-analysis

Medicine (United States)

Volumn 93, Issue 19, 2014, Pages

  Jing, Huiquan ^a,b   Dai, Fei ^c   Zhao, Chuntao ^e   Yang, Juan ^c   Li, Lizhuo ^b   Kota, Pravina ^f   Mao, Lijuan ^c   Xiang, Kaimin ^d   Zheng, Changqing ^b   Yang, Jingyun ^g,h  

^a PEKING UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

^c MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^g RUSH UNIVERSITY MEDICAL CENTER   (United States)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ASIAN; BIBLIOGRAPHIC DATABASE; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; COCHRANE LIBRARY; DNA METHYLATION; E CADHERIN GENE; EPIGENETICS; ETHNIC DIFFERENCE; GENE CONTROL; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC VARIABILITY; GOOGLE SCHOLAR; HUGE; HUMAN; MEDLINE; PROMOTER REGION; PUBLISHING; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TUMOR GENE; WEB OF SCIENCE; BIOLOGICAL MODEL; ETHNIC GROUP; ETHNOLOGY; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; STOMACH TUMOR;

CADHERIN; CDH1 PROTEIN, HUMAN; TUMOR MARKER;

CADHERINS; DNA METHYLATION; EPIGENESIS, GENETIC; ETHNIC GROUPS; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MODELS, GENETIC; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84916233750     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000107     Document Type: Article

References (60)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
2. Lauren P. Histogenesis of intestinal and diffuse types of gastric carcinoma. Scand J Gastroenterol Suppl. 1991;180:160-164.
3. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histoclinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
4. Cavaleiro-Pinto M, Peleteiro B, Lunet N, et al. Helicobacter pylori infection and gastric cardia cancer: systematic review and metaanalysis. Cancer Causes Control. 2011;22:375-387.
5. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241.
6. You WC, Zhang L, Gail MH, et al. Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C, and other risk factors. J Natl Cancer Inst. 2000;92:1607-1612.
7. Ji BT, ChowWH, Yang G, et al. The influence of cigarette smoking, alcohol, and green tea consumption on the risk of carcinoma of the cardia and distal stomach in Shanghai, China. Cancer. 1996;77:2449-2457.
8. Joossens JV, Hill MJ, Elliott P, et al. Dietary salt, nitrate and stomach cancer mortality in 24 countries. European Cancer Prevention (ECP) and the INTERSALT Cooperative Research Group. Int J Epidemiol. 1996;25:494-504.
9. Shimazu T, Wakai K, Tamakoshi A, et al. Association of vegetable and fruit intake with gastric cancer risk among Japanese: a pooled analysis of four cohort studies. Ann Oncol. 2014;25:1228-1233.
10. Hamilton JP, Meltzer SJ. A review of the genomics of gastric cancer. Clin Gastroenterol Hepatol. 2006;4:416-425.
11. Gianfagna F, De Feo E, van Duijn CM, et al. A systematic review of meta-analyses on gene polymorphisms and gastric cancer risk. Curr Genomics. 2008;9:361-374.
12. Graziano F, Humar B, Guilford P. The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. Ann Oncol. 2003;14:1705-1713.
13. Li LC, Chui RM, Sasaki M, et al. A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res. 2000;60:873-876.
14. Wang L, Wang G, Lu C, et al. Contribution of the -160C/A polymorphism in the E-cadherin promoter to cancer risk: a metaanalysis of 47 case-control studies. PLoS One. 2012;7:e40219.
15. Li YL, Tian Z, Zhang JB, et al. CDH1 promoter polymorphism and stomach cancer susceptibility. Mol Biol Rep. 2012;39:1283-1286.
16. Cui Y, Xue H, Lin B, et al. A meta-analysis of CDH1 C-160A genetic polymorphism and gastric cancer risk. DNA Cell Biol. 2011;30:937-945.
17. Chen B, Zhou Y, Yang P, et al. CDH1 -160C> a gene polymorphism is an ethnicity-dependent risk factor for gastric cancer. Cytokine. 2011;55:266-273.
18. Loh M, Koh KX, Yeo BH, et al. Meta-analysis of genetic polymorphisms and gastric cancer risk: variability in associations according to race. Eur J Cancer. 2009;45:2562-2568.
19. Gao L, Nieters A, Brenner H. Meta-analysis: tumour invasionrelated genetic polymorphisms and gastric cancer susceptibility. Aliment Pharmacol Ther. 2008;28:565-573.
20. Wang GY, Lu CQ, Zhang RM, et al. The E-cadherin gene polymorphism 160C->A and cancer risk: a HuGE review and meta-analysis of 26 case-control studies. Am J Epidemiol. 2008;167:7-14.
21. Yamada H, Shinmura K, Ikeda S, et al. Association between CDH1 haplotypes and gastric cancer risk in a Japanese population. Scand J Gastroenterol. 2007;42:1479-1485.
22. Humar B, Graziano F, Cascinu S, et al. Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene. 2002;21:8192-8195.
23. Fisher RA. Statistical Methods for Research Workers. Edinburgh: Oliver and Boyd; 1932.
24. Simes RJ. An improved Bonferroni procedure for multiple tests of significance. Biometrika. 1986;73:751-754.
25. Hartung J. A note on combining dependent tests of significance. Biometrical J. 1999;41:849-856.
26. Sheng X, Yang J. Truncated product methods for panel unit root tests. Oxford B Econ Stat. 2013;75:624-636.
27. Zaykin DV, Zhivotovsky LA, Westfall PH, et al. Truncated product method for combining P-values. Genetic Epidemiol. 2002;22: 170-185.
28. Wang H, Dong S, Xu H, et al. Genetic variants in FTO associated with metabolic syndrome: a meta- and gene-based analysis. Mol Biol Rep. 2012;39:5691-5698.
29. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
30. Wu MS, Huang SP, Chang YT, et al. Association of the -160C - a promoter polymorphism of E-cadherin gene with gastric carcinoma risk. Cancer. 2002;94:1443-1448.
31. Pharoah PD, Oliveira C, Machado JC, et al. CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer. Int J Cancer. 2002;101:196-197.
32. Kuraoka K, Oue N, Yokozaki H, et al. Correlation of a single nucleotide polymorphism in the E-cadherin gene promoter with tumorigenesis and progression of gastric carcinoma in Japan. Int J Oncol. 2003;23:421-427.
33. Park WS, Cho YG, Park JY, et al. A single nucleotide polymorphism in the E-cadherin gene promoter-160 is not associated with risk of Korean gastric cancer. J Korean Med Sci. 2003;18:501-504.
34. Shin Y, Kim IJ, Kang HC, et al. The E-cadherin -347G->GA promoter polymorphism and its effect on transcriptional regulation. Carcinogenesis. 2004;25:895-899.
35. Lu Y, Xu YC, Shen J, et al. E-cadherin gene C-160A promoter polymorphism and risk of non-cardia gastric cancer in a Chinese population. World J Gastroenterol. 2005;11:56-60.
36. Cattaneo F, Venesio T, Molatore S, et al. Functional analysis and case-control study of -160C/A polymorphism in the E-cadherin gene promoter: association with cancer risk. Anticancer Res. 2006;26:4627-4632.
37. Medina-Franco H, Ramos-De la Medina A, Vizcaino G, et al. Single nucleotide polymorphisms in the promoter region of the E-cadherin gene in gastric cancer: case-control study in a young Mexican population. Ann Surg Oncol. 2007;14:2246-2249.
38. Jenab M, McKay JD, Ferrari P, et al. CDH1 gene polymorphisms, smoking, Helicobacter pylori infection and the risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Eur J Cancer. 2008;44:774-780.
39. Zhang B, Pan K, Liu Z, et al. Genetic polymorphisms of the Ecadherin promoter and risk of sporadic gastric carcinoma in Chinese populations. Cancer Epidemiol Biomarkers Prev. 2008;17: 2402-2408.
40. Zhang XF, Wang YM, Ge H. et al. Association of CDH1 single nucleotide polymorphisms with susceptibility to esophageal squamous cell carcinomas and gastric cardia carcinomas. Dis Esophagus. 2008;21:21-29.
41. Corso G, Berardi A, Marrelli D, et al. CDH1 C-160A promoter polymorphism and gastric cancer risk. Eur J Cancer Prev. 2009;18:46-49.
42. Al-Moundhri MS, Al-Khanbashi M, Al-Kindi M, et al. Association of E-cadherin (CDH1) gene polymorphisms and gastric cancer risk. World J Gastroenterol. 2010;16:3432-3436.
43. Borges Bdo N, Santos Eda S, Bastos CE, et al. Promoter polymorphisms and methylation of E-cadherin (CDH1) and KIT in gastric cancer patients from northern Brazil. Anticancer Res. 2010;30:2225-2233.
44. Zhan Z, Wu J, Zhang JF, et al. CDH1 gene polymorphisms, plasma CDH1 levels and risk of gastric cancer in a Chinese population. Mol Biol Rep. 2012;39:8107-8113.
45. Menbari MN, Rahmani SA, Zandi F, et al. Evaluation of E-cadherin (CDH1) gene polymorphism related to gastric cancer in Kurdish population. Life Sci J. 2013;10:212-216.
46. Nasri S, More H, Graziano F, et al. A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: a case control study in an Italian population. BMC Cancer. 2008;8:138.
47. Li Y, Tang Y, Zhou R, et al. Genetic polymorphism in the 30- untranslated region of the E-cadherin gene is associated with risk of different cancers. Mol Carcinog. 2011;50:857-862.
48. To KF, Leung WK, Lee TL, et al. Promoter hypermethylation of tumor-related genes in gastric intestinal metaplasia of patients with and without gastric cancer. Int J Cancer. 2002;102:623-628.
49. Oue N, Mitani Y, Motoshita J, et al. Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer. 2006;106:1250-1259.
50. Tan SH, Ida H, Lau QC, et al. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep. 2007;18:1225-1230.
51. Zhang KL, Sun Y, Li Y, et al. Increased frequency of CpG island methylator phenotype and CDH1 methylation in a gastric cancer high-risk region of China. Transl Oncol. 2008;1:28-35.
52. Poplawski T, Tomaszewska K, Galicki M, et al. Promoter methylation of cancer-related genes in gastric carcinoma. Exp Oncol. 2008;30:112-116.
53. Tahara T, Shibata T, Nakamura M, et al. Increased number of CpG island hypermethylation in tumor suppressor genes of non-neoplastic gastric mucosa correlates with higher risk of gastric cancer. Digestion. 2010;82:27-36.
54. Yu QM, Wang XB, Luo J, et al. CDH1 methylation in preoperative peritoneal washes is an independent prognostic factor for gastric cancer. J Surg Oncol. 2012;106:765-771.
55. Nomura T, Tahara T, Shiroeda H, et al. Influence of HRH2 promoter polymorphism on aberrant DNA methylation of DAPK and CDH1 in the gastric epithelium. BMC Gastroenterol. 2013;13:1.
56. Zhang Y, Liu X, Fan Y, et al. Germline mutations and polymorphic variants in MMR, E-cadherin and MYH genes associated with familial gastric cancer in Jiangsu of China. Int J Cancer. 2006;119:2592-2596.
57. Chu CM, Chen CJ, Chan DC, et al. CDH1 polymorphisms and haplotypes in sporadic diffuse and intestinal gastric cancer: a case-control study based on direct sequencing analysis. World J Surg Oncol. 2014;12:80.
58. Kim J, Min SY, Lee HE, et al. Aberrant DNA methylation and tumor suppressive activity of the EBF3 gene in gastric carcinoma. Int J Cancer. 2012;130:817-826.
59. Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012;61:673-684.
60. Fan B, Dachrut S, Coral H, et al. Integration of DNA copy number alterations and transcriptional expression analysis in human gastric cancer. PLoS One. 2012;7:e29824.